Craig Hartigan, PA
Medical · Allentown, PANPI 1407901127
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.6%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by AbbVie at 50.0% of the total. Reporting peaked in 2021 at $10,852 and has fallen 71.8% since, to $3,064 in 2025. Among medical clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 175 payments — averaging $180.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$16K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$8K
- Gilead$1K
- Madrigal Pharmaceuticals$1K
- E.r. Squibb & Sons, L.L.C.$943
- Intercept Pharmaceuticals, Inc.$617
- plus $4K from 16 others
What the payments were for
- Speaking & faculty fees$17,21055%
- Travel & lodging$1,4495%
- Food & beverage$12,88241%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 68 | $15,773 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 38 | $8,400 |
| Gilead | 11 | $1,149 |
| Madrigal Pharmaceuticals | 8 | $1,089 |
| E.r. Squibb & Sons, L.L.C. | 8 | $943 |
| Intercept Pharmaceuticals, Inc. | 7 | $617 |
| Ardelyx, Inc. | 5 | $551 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $468 |
| Johnson & Johnson | 3 | $399 |
| Regeneron Healthcare Solutions, Inc. | 3 | $374 |
| Nestle Healthcare Nutrition Inc. | 5 | $372 |
| Janssen Scientific Affairs, LLC | 2 | $250 |
| Evoke Pharma, Inc. | 2 | $226 |
| Intra-sana Laboratories | 2 | $142 |
| Aimmune Therapeutics, Inc. | 1 | $125 |
| Novo Nordisk | 1 | $125 |
| Sanofi | 1 | $120 |
| Medtronic | 2 | $116 |
| Ipsen Biopharmaceuticals, Inc | 1 | $105 |
| Endogastric Solutions, Inc | 1 | $96 |
| Mallinckrodt Hospital Products Inc. | 1 | $68 |
| Bristol Myers Squibb | 1 | $31 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$31,541 in reported general payments places this provider in the 95th percentile of 2,594 medical providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 55 | $43,225 |
| CreonLipase/Protease/Amylase | 16 | $31,048 |
| MotegrityPrucalopride Succinate | 20 | $14,865 |
| Mesalamine | 39 | $9,359 |
| Dexlansoprazole DrDexlansoprazole | 12 | $5,168 |
| CholestyramineCholestyramine (With Sugar) | 48 | $4,534 |
| Pantoprazole Sodium | 315 | $4,423 |
| Famotidine | 189 | $2,945 |
| Omeprazole | 176 | $2,421 |
| Esomeprazole Magnesium | 37 | $1,644 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 85 | $1,304 |
| Dicyclomine Hcl | 76 | $1,056 |
| Colestipol Hcl | 15 | $838 |
| Sucralfate | 15 | $715 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 31 | $385 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess, Creon | $15,773 | $74,27371 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $468 | $14,86520 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,594 medical providers in Pennsylvania.
Other medical in Allentown
- Christopher WolfeAllentown$13K
- Danielle WestgateAllentown$12K
- Jacqueline KernaghanSpringfield$426K
- Drew SodaNew Hope$220K
- Angela KapalkoPhiladelphia$123K
- Linda PerryPhiladelphia$123K
- Cory DavidsonErie$119K
- Shelley SassamanTamaqua$90K
- Meghan HoffnerBethlehem$86K
- Thomas IacovoniDanville$72K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.